アブストラクト
Japanese
| Title | 非小細胞肺癌1次治療における免疫関連有害事象の発現予測因子について |
|---|---|
| Subtitle | ノート |
| Authors | 田口伸†, 和地徹, 佐藤優弥, 柳田真樹子 |
| Authors (kana) | |
| Organization | †秋田赤十字病院薬剤部 |
| Journal | 医薬品相互作用研究 |
| Volume | 48 |
| Number | 1 |
| Page | 8-12 |
| Year/Month | 2024 / |
| Article | 報告 |
| Publisher | 医薬品相互作用研究会 |
| Abstract | 「緒言」肺癌診療ガイドライン2022年版では, 免疫チェックポイント阻害薬(immune checkpoint inhibitor: ICI)は進行性非小細胞肺癌の標準治療薬となっている. しかしながら, ICI治療における免疫関連副作用(immune-related adverse effect: irAE)の多くは可逆的であるものの, 稀に生命を脅かす可能性もある. 特に大腸炎, 肝炎, 肺炎, 甲状腺機能低下症, 甲状腺機能亢進症などのirAEは, 皮膚, 大腸, 内分泌器官, 肝臓, 肺など複数の臓器系に影響を与える. 最近の質の高いメタアナリシスでは, 全身性炎症反応増加の指標である好中球・リンパ球比(neutrophil-to-lymphocyte ratio: NLR)が, 非小細胞肺癌を含むさまざまな固形癌の予後因子であることが示された. |
| Practice | 薬学 |
| Keywords | non-small-cell lung cancer, Immune checkpoint inhibitors, immune-related adverse effect, platelet counts, platelet-lymphocyte ratio |
English
| Title | Predictors of immune-related adverse events in the primary treatment of non-small-cell lung cancer |
|---|---|
| Subtitle | |
| Authors | Shin TAGUCHI†, Toru WACHI, Yuya SATO, Makiko YANAGIDA |
| Authors (kana) | |
| Organization | †Department of Pharmacy, Japanese Red Cross Akita Hospital |
| Journal | Journal of Drug Interaction Research |
| Volume | 48 |
| Number | 1 |
| Page | 8-12 |
| Year/Month | 2024 / |
| Article | Report |
| Publisher | Research On Drug Interactions |
| Abstract | [Abstract] Immune checkpoint inhibitors (ICI) are considered the standard of care for the first-line treatment of non-small-cell lung cancer; however, few studies have conclusively reported factors associated with immune-related adverse effect (irAE) following ICI therapy initiation. In this study, we investigated factors associated with the development of irAE in patients in whom ICI therapy was initiated as the first-line treatment of non-small-cell lung cancer at Akita Red Cross Hospital. The average survey on irAE duration for this study was 200.6 +- 147.4 days. The results showed that the irAE group had significantly higher platelet counts and a higher platelet-lymphocyte ratio (PLR) before treatment initiation. A receiver operating characteristic curve was generated to calculate the cutoff values based on the detection of irAE to clarify the index of high-risk patients with irAE at ICI initiation. The platelet count was 32.4 * 104/μL and the PLR was 226.9. This study highlights the importance of measuring the pre-treatment platelet count and PLR as predictors of irAE in patients with non-small-cell lung cancer, who receive ICI as the first-line therapy. |
| Practice | Pharmaceutical sciences |
| Keywords | non-small-cell lung cancer, Immune checkpoint inhibitors, immune-related adverse effect, platelet counts, platelet-lymphocyte ratio |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
